Your browser doesn't support javascript.
loading
Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial.
Rymut, Sharon M; Sukumaran, Siddharth; Sperinde, Gizette; Bremer, Meire; Galanter, Joshua; Yoshida, Kenta; Smith, Jordan; Banerjee, Prajna; Sverkos, Viyia; Cai, Fang; Steffen, Verena; Henderson, Lindsay M; Rhee, Horace; Belloni, Paula N; Lin, Joseph H; Staton, Tracy L.
Afiliación
  • Rymut SM; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Sukumaran S; Department of Preclinical and Translational PKPD, Genentech, Inc., South San Francisco, California, USA.
  • Sperinde G; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA.
  • Bremer M; Department of Ophthalmology, Metabolism, Neurology, and Immunology Biomarker Development (OMNI-BD), Genentech, Inc., South San Francisco, California, USA.
  • Galanter J; Department of Safety Science, Genentech, Inc., South San Francisco, California, USA.
  • Yoshida K; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Smith J; Department of Biostatistics, F. Hoffmann-La Roche, Mississauga, Ontario, Canada.
  • Banerjee P; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, USA.
  • Sverkos V; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA.
  • Cai F; Department of Ophthalmology, Metabolism, Neurology, and Immunology Biomarker Development (OMNI-BD), Genentech, Inc., South San Francisco, California, USA.
  • Steffen V; Department of Biostatistics, Genentech, Inc., South San Francisco, California, USA.
  • Henderson LM; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Rhee H; Early Clinical Development, Ophthalmology, Metabolism, Neurology, and Immunology (OMNI), Genentech, Inc., South San Francisco, California, USA.
  • Belloni PN; Early Clinical Development, Ophthalmology, Metabolism, Neurology, and Immunology (OMNI), Genentech, Inc., South San Francisco, California, USA.
  • Lin JH; Early Clinical Development, Ophthalmology, Metabolism, Neurology, and Immunology (OMNI), Genentech, Inc., South San Francisco, California, USA.
  • Staton TL; Department of Ophthalmology, Metabolism, Neurology, and Immunology Biomarker Development (OMNI-BD), Genentech, Inc., South San Francisco, California, USA.
Clin Transl Sci ; 15(2): 451-463, 2022 02.
Article en En | MEDLINE | ID: mdl-34581002
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Transl Sci Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Transl Sci Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos